Trial Profile
A Randomized, Active-controlled, Open Label, 2-treatment Arm, and Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/Lixisenatide Combination to Lixisenatide on Top of OADs in Japanese Patients With Type 2 DM With an Extension Period
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin-glargine/lixisenatide (Primary) ; Lixisenatide
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms LIXILAN JP-O1
- Sponsors Sanofi
- 15 Apr 2020 Primary endpoint (Change from baseline in HbA1c) has been met.
- 15 Apr 2020 Results published in the Diabetes Care
- 10 Jul 2018 Status changed from active, no longer recruiting to completed.